June 18 (Reuters) - Knight Therapeutics Inc GUD.TO :
* MEDIMETRIKS PHARMACEUTICALS FOCUSES ON ADVANCING MM36 (DIFAMILAST) THROUGH PHASE 3 TRIALS; EXTINGUISHES DEBT OWED TO KNIGHT THERAPEUTICS
* MEDIMETRIKS PHARMA - IS IN DISCUSSIONS FOR FINANCING OPTIONS TO ADVANCE MM36 (DIFAMILAST) THROUGH PHASE 3 PIVOTAL TRIALS AND POTENTIAL FDA APPROVAL
* MEDIMETRIKS PHARMACEUTICALS - COMPANY EXTINGUISHED FINAL DEBT OWED KNIGHT THERAPEUTICS AND IS NOW FREE OF THIRD PARTY DEBT